[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201909406VA - Treatment of adipocytes - Google Patents

Treatment of adipocytes

Info

Publication number
SG11201909406VA
SG11201909406VA SG11201909406VA SG11201909406VA SG 11201909406V A SG11201909406V A SG 11201909406VA SG 11201909406V A SG11201909406V A SG 11201909406VA SG 11201909406V A SG11201909406V A SG 11201909406VA
Authority
SG
Singapore
Prior art keywords
international
louisiana
exton
suite
springdale
Prior art date
Application number
Other languages
English (en)
Inventor
Andrew G Reaume
Weina Cong
Frank Greenway
Ann Coulter
Original Assignee
Melior Pharmaceuticals I Inc
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Pharmaceuticals I Inc, Univ Louisiana State filed Critical Melior Pharmaceuticals I Inc
Publication of SG11201909406VA publication Critical patent/SG11201909406VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
SG11201909406V 2017-04-10 2018-04-09 Treatment of adipocytes SG11201909406VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483584P 2017-04-10 2017-04-10
PCT/US2018/026707 WO2018191166A1 (en) 2017-04-10 2018-04-09 Treatment of adipocytes

Publications (1)

Publication Number Publication Date
SG11201909406VA true SG11201909406VA (en) 2019-11-28

Family

ID=63710133

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909406V SG11201909406VA (en) 2017-04-10 2018-04-09 Treatment of adipocytes

Country Status (13)

Country Link
US (3) US10786503B2 (zh)
EP (1) EP3609500B1 (zh)
JP (1) JP7182605B2 (zh)
KR (1) KR102634575B1 (zh)
CN (1) CN110785170B (zh)
AU (1) AU2018250795B2 (zh)
CA (1) CA3059432A1 (zh)
IL (1) IL269789B (zh)
MX (1) MX2019012170A (zh)
NZ (1) NZ758966A (zh)
SG (1) SG11201909406VA (zh)
WO (1) WO2018191166A1 (zh)
ZA (1) ZA201907401B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024863A2 (en) 2005-08-22 2007-03-01 Melior Discovery, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
SG11201403207WA (en) * 2011-12-12 2014-09-26 Melior Pharmaceuticals I Inc Treatment of type i and type ii diabetes
SG11201909406VA (en) 2017-04-10 2019-11-28 Melior Pharmaceuticals I Inc Treatment of adipocytes
CN110302204A (zh) * 2019-07-10 2019-10-08 北京大学第三医院（北京大学第三临床医学院） 一种用于糖尿病治疗的药物
US20220031700A1 (en) * 2020-07-30 2022-02-03 Melior Pharmaceuticals I, Inc. Treatment of Acute Respiratory Distress Syndrome (ARDS)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
BE790125A (fr) 1971-10-29 1973-04-16 Pfizer Nouvelles pyrimidinones et nouvelles hydroxypyrimidines
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
US4080454A (en) 1976-07-16 1978-03-21 Pfizer Inc. 5-M-Tolyloxyuracil, anti-ulcer agent
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9214720D0 (en) 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US6900304B2 (en) 1996-01-31 2005-05-31 The Regents Of The University Of California Emission ratiometric indicators of phosphorylation
US20020019346A1 (en) 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6410255B1 (en) 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
MXPA05011523A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
US20050208054A1 (en) 2003-12-09 2005-09-22 University Of Massachusetts Methods of identifying insulin response modulators and uses therefor
EP1541694A1 (en) 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
US20060035302A1 (en) 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
WO2007016975A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Kinase and phosphatase assays based on fret
US20070025953A1 (en) 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
WO2007024863A2 (en) 2005-08-22 2007-03-01 Melior Discovery, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
JP4850914B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
JP2007080357A (ja) * 2005-09-13 2007-03-29 Toshiba Corp 情報記憶媒体、情報再生方法、情報再生装置
AU2008279242A1 (en) 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating IRS-1 and AKT
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2010078300A1 (en) 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
WO2015127474A1 (en) * 2014-02-24 2015-08-27 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
SG11201909406VA (en) 2017-04-10 2019-11-28 Melior Pharmaceuticals I Inc Treatment of adipocytes

Also Published As

Publication number Publication date
NZ758966A (en) 2024-08-30
US11534442B2 (en) 2022-12-27
US20230149404A1 (en) 2023-05-18
IL269789A (en) 2019-11-28
AU2018250795A1 (en) 2019-11-28
EP3609500A1 (en) 2020-02-19
CN110785170A (zh) 2020-02-11
US12064432B2 (en) 2024-08-20
JP7182605B2 (ja) 2022-12-02
US20180289707A1 (en) 2018-10-11
EP3609500B1 (en) 2024-11-13
KR20190133245A (ko) 2019-12-02
MX2019012170A (es) 2020-01-20
JP2020513038A (ja) 2020-04-30
CA3059432A1 (en) 2018-10-18
WO2018191166A1 (en) 2018-10-18
BR112019021140A2 (pt) 2020-05-19
US10786503B2 (en) 2020-09-29
EP3609500A4 (en) 2020-08-19
ZA201907401B (en) 2022-03-30
AU2018250795B2 (en) 2022-02-10
CN110785170B (zh) 2023-03-28
KR102634575B1 (ko) 2024-02-06
IL269789B (en) 2022-05-01
US20210128558A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
SG11201909406VA (en) Treatment of adipocytes
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201808990QA (en) Compositions for topical application of compounds
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201909949XA (en) Targeted immunotolerance
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201900157RA (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201408174UA (en) Antibody formulation
SG11201906301UA (en) Methods of manufacture of nut flours and formulations for oral immunotherapy
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201903946SA (en) Devices and methods for slurry generation
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201804577RA (en) Fgf21 variants
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201907023UA (en) Method of reducing neutropenia
SG11201806018YA (en) Protein cage-stabilized pickering emulsions and the use thereof